Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A, -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (2115)	1/14/2008 9:39:21 AM
From: Jibacoa	Read Replies (1) \| Respond to of 3722

CEGE was up about 4.62% in premarket, but is up only 3.16% at present.<g> bigcharts.marketwatch.com It announced today that the IDMC for VITAL-1., (the PIII of its GVAX for prostate cancer), has completed an interim analysis & recommended that the study continue.The IDMC provided no information other than was OK to continue the trial. GVAX estimates that it will have enough data to conduct the final analysis in the second half of 2009. The primary endpoint is an improvement in survival. VITAL-1 was initiated in July 2004 & completed recruitment of 626 patients in July 2007. CEGE has another GVAX PIII, VITAL-2,which is designed to evaluate safety & efficacy when used in combination with Taxotere chemo compared with Taxotere chemo & prednisone in HRPC patients with metastatic disease.The primary endpoint of that trial is also improvement in survival. In spite of its persistent losses, CEGE has been forming a little base at the $2 level. In March-April of last Yr. it had a good run from the $2.79 to the $7.30 level, but it needs to close above $2.75 in order to get off from its near term DT.<g> bigcharts.marketwatch.com Bernard